Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents

Area of Science:

• Cardiology
• Medical Imaging
• Pharmacovigilance

Background:

• The U.S. Food and Drug Administration issued a black box warning in 2007 for echocardiography contrast agents, restricting their use in specific high-risk patient groups.
• Concerns were raised regarding potential adverse effects, including myocardial infarction and all-cause mortality, associated with these contrast agents.

Purpose of the Study:

• To conduct a systematic review and meta-analysis to evaluate the safety of contrast agents used in echocardiography.
• To assess the association between contrast agent use and the incidence of myocardial infarction and all-cause mortality.

Main Methods:

• A systematic literature search was performed across MEDLINE, EMBASE, BIOSIS, and Cochrane databases (inception to October 2009).
• Eight studies reporting myocardial infarction and/or all-cause mortality outcomes after echocardiography with contrast agents were included.
• A random-effect model was employed to pool data, with heterogeneity assessed using I(2) statistics.

Main Results:

• The incidence of death was 0.34% in the contrast group versus 0.9% in the non-contrast group (pooled odds ratio: 0.57; 95% CI: 0.32 to 1.01, p=0.05).
• The incidence of myocardial infarction was 0.15% in the contrast group versus 0.2% in the non-contrast group (pooled odds ratio: 0.85; 95% CI: 0.35 to 2.05, p=0.72).
• Significant heterogeneity was observed among the included studies.

Conclusions:

• The cumulative evidence suggests that contrast agents used for echocardiography are safe.
• Their use is not associated with an increased incidence of myocardial infarction or all-cause mortality compared to non-contrast procedures.